Masitinib for the Treatment of Alzheimer’s Disease

References

• Le Cesne A , BlayJ-Y, BuiBNet al. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumor (GIST). Eur. J. Cancer, 46(8), 1344–1351 (2010).
   PubMed Web of Science ®Google Scholar
• Adenis A , BlayJ-Y, Bui-NguyenBet al. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial. Ann. Oncol., 25(9), 1762–1769 (2014).
   PubMed Web of Science ®Google Scholar
• Dubreuil P , LetardS, CiufoliniMet al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE, 4(9), e7258 (2009).
   PubMed Web of Science ®Google Scholar
• Marech I , PatrunoR, ZizzoNet al. Masitinib (AB1010), from canine tumor model to human clinical development: where we are? Crit. Rev. Oncol. Hematol., 91(1), 98–111 (2014).
   PubMed Web of Science ®Google Scholar
• Demetri GD . Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin. Oncol., 38, S10–S19 (2011).
   PubMed Web of Science ®Google Scholar
• Soria JC , MassardC, MagnéNet al. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur. J. Cancer, 45(13), 2333–2341 (2009).
   PubMed Web of Science ®Google Scholar
• Aljoundi AK , AgoniC, OlotuFA, SolimanME. ‘Piperazining’ the catalytic gatekeepers: unraveling the pan-inhibition of SRC kinases; LYN, FYN and BLK by masitinib. Future Med. Chem., 11(18), 2365–2380 (2019).
   PubMed Web of Science ®Google Scholar
• Shirazi SK , WoodJG. The protein tyrosine kinase, fyn, in Alzheimer’s disease pathology. Neuroreport, 4(4), 435–437 (1993).
   PubMed Web of Science ®Google Scholar
• Lee G , ThangavelR, SharmaVMet al. Phosphorylation of tau by fyn: implications for Alzheimer’s disease. J. Neurosci., 24(9), 2304–2312 (2004).
   PubMed Web of Science ®Google Scholar
• Tebib J , MarietteX, BourgeoisPet al. Masitinib in the treatment of active rheumatoid arthritis: results of a multicenter, open-label, dose-ranging, Phase IIa study. Arthritis Res. Ther., 11(3), R95 (2009).
   PubMed Web of Science ®Google Scholar
• AB Science announces that Phase IIb/III study evaluating oral in Alzheimer’s disease met its primary endpoint. (2020). https://www.globenewswire.com/news-release/2020/12/16/2145869/0/en/AB-Science-announces-that-Phase-2B-3-study-evaluating-oral-in-Alzheimer-s-disease-met-its-primary-endpoint.html
   Google Scholar
• Li T , MartinE, AbadaYSet al. Effects of chronic masitinib treatment in APPswe/PSEN1dE9 transgenic mice modeling Alzheimer’s disease. J. Alzheimers Dis., 76(4), 1339–1345 (2020).
   PubMed Web of Science ®Google Scholar
• Lonskaya I , HebronML, SelbySTet al. Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer’s disease models. Neuroscience, 24(304), 316–327 (2015).
   Google Scholar
• Lonskaya I , HebronML, DesforgesNM, FranjieA, MoussaCE. Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance. EMBO Mol. Med., 5(8), 1247–1262 (2013).
   PubMed Web of Science ®Google Scholar
• Cummings J , LeeG, RitterA, SabbaghM, ZhongK. Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement (N Y)., 6(1), e12050 (2020).
   PubMedGoogle Scholar
• Cummings JL , TongG, BallardC. Treatment combinations for Alzheimer’s disease: current and future pharmacotherapy options. J. Alzheimer’s Dis., 67(3), 779–794 (2019).
   PubMed Web of Science ®Google Scholar
• Cummings J , FeldmanHH, ScheltensP. The ‘rights’ of precision drug development for Alzheimer’s disease. Alzheimers Res. Ther., 11(1), 76 (2019).
   PubMed Web of Science ®Google Scholar
• Sandhu JK , KulkaM. Decoding mast cell-microglia communication in neurodegenerative diseases. Int. J. Mol. Sci., 22, 1093 (2021).
   PubMed Web of Science ®Google Scholar
• Skaper SD , FacciL, KeeWJ, StrijbosPJ. Potentiation by histamine of synaptically mediated excitotoxicity in cultured hippocampal neurones: a possible role for mast cells. J. Neurochem., 76(1), 47–55 (2001).
   PubMed Web of Science ®Google Scholar
• Skaper S , GiustiP, FacciL. Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB J., 26(8), 3103–3117 (2012).
   PubMed Web of Science ®Google Scholar
• Skaper S , FacciL, GiustiP. Mast cells, glia and neuroinflammation: partners in crime?Immunology, 141(3), 314–327 (2014a).
   PubMed Web of Science ®Google Scholar
• Skaper SD , FacciL, GiustiP. Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: a review. CNS Neurol. Disord. Drug Targets, 13(10), 1654–1666 (2014b).
   PubMed Web of Science ®Google Scholar
• Skaper SD . Mast cell-glia dialogue in chronic pain and neuropathic pain: blood-brain barrier implications. CNS Neurol. Disord. Drug Targets, 15(9), 1072–1078 (2016).
   PubMed Web of Science ®Google Scholar
• Anastassiadis T , DeaconSW, DevarajanKet al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol., 29(11), 1039–1045 (2011).
   PubMed Web of Science ®Google Scholar
• Tang SJ , Fesharaki-ZadehA, TakahashiHet al. Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic and traumatic Tauopathy. Acta Neuropathol. Commun., 8(1), 96 (2020).
   PubMed Web of Science ®Google Scholar
• Liu G , FiockKL, LevitesYet al. Fyn depletion ameliorates tau(P301L)-induced neuropathology. Acta Neuropathol. Commun., 8(1), 108 (2020).
   PubMed Web of Science ®Google Scholar
• Chin J , PalopJJ, PuoliväliJet al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer’s disease. J. Neurosci., 25(42), 9694–9703 (2005).
   PubMed Web of Science ®Google Scholar
• Roberson ED , HalabiskyB, YooJWet al. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer’s disease. J. Neurosci., 31(2), 700–711 (2011).
   PubMed Web of Science ®Google Scholar
• Tang SJ , Fesharaki-ZadehA, TakahashiHet al. Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic and traumatic Tauopathy. Acta Neuropathol. Commun., 8(1), 96 (2020).
   PubMed Web of Science ®Google Scholar
• Tezuka T , UmemoriH, AkiyamaTet al. PSD-95 promotes Fyn-mediated tyrosine phosphorylation of the N-methyl-D-aspartate receptor subunit NR2A. Proc. Natl Acad. Sci. USA, 96, 435–440 (1999).
   PubMed Web of Science ®Google Scholar
• Trepanier CH , JacksonMF, MacDonaldJF. Regulation of NMDA receptors by the tyrosine kinase Fyn. FEBS J., 279, 12–19 (2012).
   PubMed Web of Science ®Google Scholar
• Dementia . http://www.who.int/news-room/fact-sheets/detail/dementia
   Google Scholar
• 2021 Alzheimer’s disease facts and figures. Alzheimers Dement., 17(3), 327–406(2021).
   PubMed Web of Science ®Google Scholar
• Ittner LM , KeYD, DelerueF, BiMet al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell, 142, 387–397 (2010).
   PubMed Web of Science ®Google Scholar
• Lopes S , Vaz-SilvaJ, PintoVet al. Tau protein is essential for stress-induced brain pathology. Proc. Natl Acad. Sci. USA, 113(26), E3755–3763 (2016).
   PubMed Web of Science ®Google Scholar
• Kong C , XieH, GaoZet al. Binding between prion protein and abeta oligomers contributes to the pathogenesis of Alzheimer’s disease. Virol. Sin., 34, 475–488 (2019).
   PubMed Web of Science ®Google Scholar
• Dubreuil P , LetardS, CiufoliniMet al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PloS ONE, 4, e7258 (2009).
   PubMed Web of Science ®Google Scholar
• Williamson R , ScalesT, ClarkBRet al. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases. J. Neurosci., 22(1), 10–20 (2002).
   PubMed Web of Science ®Google Scholar
• Nygaard HB . Targeting Fyn kinase in Alzheimer’s disease. Biol. Psychiatry, 83, 369–376 (2018).
   PubMed Web of Science ®Google Scholar
• ClinicalTrial.gov . Masitinib in patients with mild-to-moderate Alzheimer’s disease. (2020). https://clinicaltrials.gov/ct2/show/NCT01872598
   Google Scholar
• AB Science press release. (2020). https://www.ab-science.com/results-from-phase-2b-3-studyevaluating-masitinib-in-alzheimers-disease/
   Google Scholar
• Yasunaga M , YagiT, HanzawaNet al. Involvement of Fyn tyrosine kinase in progression of cytokinesis of B lymphocyte progenitor. J. Cell Biol., 132(1–2), 91–99 (1996).
   PubMed Web of Science ®Google Scholar
• Bellamy F , BaderT, MoussyA, HermineO. Pharmacokinetics of masitinib in cats. Vet. Res. Commun., 33(8), 831–837 (2009).
   PubMed Web of Science ®Google Scholar
• Harcha PA , GarcésP, ArredondoC, FernándezG, SáezJC, van ZundertB. Mast cell and astrocyte hemichannels and their role in Alzheimer’s disease, ALS, and harmful stress conditions. International J. Mol. Sci., 22(4), 1924 (2021).
   PubMed Web of Science ®Google Scholar
• Harcha PA , VargasA, YiC, KoulakoffAA, GiaumeC, SáezJC. Hemichannels are required for amyloid β-peptide-induced degranulation and are activated in brain mast cells of APPswe/PS1dE9 mice. J. Neurosci., 35(25), 9526–9538 (2015).
   PubMed Web of Science ®Google Scholar
• Jones MK , NairA, GuptaM. Mast cells in neurodegenerative disease. Front. Cell Neurosci., 13, 171 (2019).
   PubMed Web of Science ®Google Scholar
• Motta C , FinardiA, TonioloSet al. Protective role of cerebrospinal fluid inflammatory cytokines in patients with amnestic mild cognitive impairment and early Alzheimer’s disease carrying apolipoprotein E4 genotype. J. Alzheimers Dis., 76(2), 681–689 (2020).
   PubMed Web of Science ®Google Scholar
• Skaper SD , FacciL, ZussoM, GiustiP. An inflammation-centric view of neurological disease: beyond the neuron. Front. Cell Neurosci., 12, 72 (2018).
   PubMed Web of Science ®Google Scholar
• Hendriksen E , van BergeijkD, OostingRS, RedegeldFA. Mast cells in neuroinflammation and brain disorders. Neurosci. Biobehav. Rev., 79, 119–133 (2017).
   PubMed Web of Science ®Google Scholar
• Shaik-Dasthagirisaheb YB , ContiP. The role of mast cells in Alzheimer’s disease. Adv. Clin. Exp. Med., 25(4), 781–787 (2016).
   PubMed Web of Science ®Google Scholar
• Sweeney MD , SagareAP, ZlokovicBV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol., 14(3), 133–150 (2018).
   PubMed Web of Science ®Google Scholar
• Lee G , ThangavelR, SharmaVMet al. Phosphorylation of tau by fyn: implications for Alzheimer’s disease. J. Neurosci., 24(9), 2304–2312 (2004).
   PubMed Web of Science ®Google Scholar
• Williamson R , ScalesT, ClarkBRet al. Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases. J. Neurosci., 22(1), 10–20 (2002).
   PubMed Web of Science ®Google Scholar
• Briner A , GötzJ, PolancoJC. Fyn kinase controls Tau aggregation in vivo. Cell Rep., 32(7), 108045 (2020).
   PubMed Web of Science ®Google Scholar
• Sette C , ParonettoMP, BarchiM, BevilacquaA, GeremiaR, RossiP. Tr-kit-induced resumption of the cell cycle in mouse eggs requires activation of a Src-like kinase. EMBO J., 21(20), 5386–5395 (2002).
   PubMed Web of Science ®Google Scholar
• Folch J , JunyentF, VerdaguerEet al. Role of cell cycle re-entry in neurons: a common apoptotic mechanism of neuronal cell death. Neurotox. Res., 22(3), 195–207 (2012).
   PubMed Web of Science ®Google Scholar
• Seward ME , SwansonE, NorambuenaAet al. Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer’s disease. J. Cell Sci., 126(Pt 5), 1278–1286 (2013).
   PubMed Web of Science ®Google Scholar
• Esposito Z , BelliL, TonioloSet al. Amyloid beta, glutamate, excitotoxicity in Alzheimer’s disease: are we on the right track? CNS Neurosci. Ther., 19(8), 549–555 (2013).
   PubMed Web of Science ®Google Scholar
• Souter S , LeeG. Tubulin-independent tau in Alzheimer’s disease and cancer: implications for disease pathogenesis and treatment. Curr. Alzheimer Res., 7(8), 697–707 (2010).
   PubMed Web of Science ®Google Scholar
• Piccioni G , MangoD, SaidiA, CorboM, NisticòR. Targeting microglia-synapse interactions in Alzheimer’s disease. Int. J. Mol. Sci., 22(5), 2342 (2021).
   PubMed Web of Science ®Google Scholar
• Ittner LM , GötzJ. Amyloid-β and tau – a toxic pas de deux in Alzheimer’s disease. Nat. Rev. Neurosci., 12(2), 65–72 (2011).
   PubMed Web of Science ®Google Scholar
• Elmore MR , NajafiAR, KoikeMAet al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron, 82, 380–397 (2014).
   PubMed Web of Science ®Google Scholar
• Trias E , IbarburuS, Barreto-NunezRet al. Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J. Neuroinflammation, 13, 177 (2016).
   PubMed Web of Science ®Google Scholar
• De Sousa VL , AraújoSB, AntonioLMet al. Innate immune memory mediates increased susceptibility to Alzheimeŕs disease-like pathology in sepsis surviving mice. Brain Behav. Immun., 7, S0889-1591(21)00158-6 (2021).
   Google Scholar
• Marzan DE , Brügger-VerdonV, WestBLet al. Activated microglia drive demyelination via CSF1R signaling. Glia, 69(6), 1583–1604 (2021).
   PubMed Web of Science ®Google Scholar
• Son Y , JeongYJ, ShinNRet al. Inhibition of colony-stimulating factor 1 receptor by PLX3397 prevents amyloid beta pathology and rescues dopaminergic signaling in aging 5xFAD mice. Int. J. Mol. Sci., 21(15), 5553 (2020).
   PubMed Web of Science ®Google Scholar
• Wang CF , ZhaoCC, LiuWLet al. Depletion of microglia attenuates dendritic spine loss and neuronal apoptosis in the acute stage of moderate traumatic brain injury in mice. J. Neurotrauma, 37(1), 43–54 (2020).
   PubMedGoogle Scholar
• Boros BD , GreathouseKM, GentryEGet al. Dendritic spines provide cognitive resilience against Alzheimer’s disease. Ann. Neurol., 82(4), 602–614 (2017).
   PubMed Web of Science ®Google Scholar
• Boros BD , GreathouseKM, GearingMet al. Dendritic spine remodeling accompanies Alzheimer’s disease pathology and genetic susceptibility in cognitively normal aging. Neurobiol. Aging, 73, 92–103 (2019).
   PubMed Web of Science ®Google Scholar
• Walker CK , HerskowitzJH. Dendritic spines: mediators of cognitive resilience in aging and Alzheimer’s disease. Neuroscientist1073858420945964 (2020).
   Web of Science ®Google Scholar
• Dumitriu D , HaoJ, HaraYet al. Selective changes in thin spine density and morphology in monkey prefrontal cortex correlate with aging-related cognitive impairment. J. Neurosci., 30(22), 7507–7515 (2010).
   PubMed Web of Science ®Google Scholar
• Lambert MP , BarlowAK, ChromyBAet al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA, 95(11), 6448–6453 (1998).
   PubMed Web of Science ®Google Scholar
• Suzuki T , Okumura-NojiK. NMDA receptor subunits epsilon 1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the postsynaptic density fraction isolated from the rat brain. Biochem. Biophys. Res. Commun., 216, 582–588 (1995).
   PubMed Web of Science ®Google Scholar
• Nakazawa T , KomaiS, TezukaTet al. Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor. J. Biol. Chem., 276, 693–699 (2001).
   PubMed Web of Science ®Google Scholar
• Haas LT , SalazarSV, KostylevMAet al. Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signaling in Alzheimer’s disease. Brain, 139(Pt 2), 526–546 (2016).
   PubMedGoogle Scholar
• Hermine O . Masitinib for the treatment of Alzheimer’s disease: clinical and preclinical data. Neurobiol. Aging, 39, S1eS13 (2016).
   Web of Science ®Google Scholar
• Ma QL , YangF, FrautschySA, ColeGM. PAK in Alzheimer disease, Huntington disease and X-linked mental retardation. Cell Logist., 2(2), 117–125 (2012).
   PubMedGoogle Scholar
• Ittner LM , KeYD, DelerueFet al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell, 142(3), 387–397 (2010).
   PubMed Web of Science ®Google Scholar
• Haass C , MandelkowE. Fyn-tau-amyloid: a toxic triad. Cell, 142(3), 356–358 (2010).
   PubMed Web of Science ®Google Scholar
• Kaufman AC , SalazarSV, HaasLTet al. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann. Neurol., 77(6), 953–971 (2015).
   PubMed Web of Science ®Google Scholar
• Lee G , NewmanST, GardDL, BandH, PanchamoorthyG. Tau interacts with src-family non-receptor tyrosine kinases. J. Cell Sci., 111(Pt 21), 3167–3177 (1998).
   PubMedGoogle Scholar
• Barry AE , KlyubinI, McDonald JMet al. Alzheimer’s disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J. Neurosci., 31, 7259–7263 (2011).
   PubMed Web of Science ®Google Scholar
• Minami SS , CliffordTG, HoeHSet al. Fyn knock-down increases Abeta, decreases phospho-tau, and worsens spatial learning in 3Tg-AD mice. Neurobiol. Aging, 33(4), 825.e15–24 (2012).
   PubMed Web of Science ®Google Scholar
• Babus LW , LittleEM, KeenoyKEet al. Decreased dendritic spine density and abnormal spine morphology in Fyn knockout mice. Brain Res., 1415, 96–102 (2011).
   PubMed Web of Science ®Google Scholar
• Toniolo S , SenA, HusainM. Modulation of brain hyperexcitability: potential new therapeutic approaches in Alzheimer’s disease. Int. J. Mol. Sci., 21(23), 9318 (2020).
   PubMed Web of Science ®Google Scholar
• Piette F , BelminJ, VincentHet al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer’s disease: a randomised, placebo-controlled Phase 2 trial. Alzheimers. Res. Ther., 3(2), 16 (2011).
   PubMed Web of Science ®Google Scholar
• Trias E , IbarburuS, Barreto-NúñezRet al. Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS. Insight, 2(20), e95934 (2017).
   Web of Science ®Google Scholar
• Trias E , KingPH, SiY, KwonYet al. Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS. JCI Insight, 3(19), e123249 (2018).
   PubMed Web of Science ®Google Scholar
• Niederhoffer N , LevyR, SickEet al. Amyloid beta peptides trigger CD47-dependent mast cell secretory and phagocytic responses. Int. J. Immunopathol. Pharmacol., 22(2), 473–483 (2009).
   PubMed Web of Science ®Google Scholar
• Fagiani F , LanniC, RacchiM, GovoniS. Targeting dementias through cancer kinases inhibition. Alzheimers Dement. (NY), 6(1), e12044 (2020).
   PubMedGoogle Scholar
• Nygaard HB , WagnerAF, BowenGSet al. A Phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease. Alzheimers Res. Ther., 7(1), 35 (2015).
   PubMedGoogle Scholar
• Van Dyck CH , NygaardHB, ChenKet al. Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease: a randomized clinical trial. JAMA Neurol., 76(10), 1219–1229 (2019).
   PubMed Web of Science ®Google Scholar
• Calabrò M , RinaldiC, SantoroG, CrisafulliC. The biological pathways of Alzheimer disease: a review. AIMS Neurosci., 8(1), 86–132 (2020).
   PubMed Web of Science ®Google Scholar
• Ray WJ , Buggia-PrevotV. Novel targets for Alzheimer’s disease: a view beyond amyloid. Annu. Rev. Med., 72, 15–28 (2021).
   PubMed Web of Science ®Google Scholar
• Xiao S , ChanP, WangTet al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase III clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia. Alzheimers Res Ther., 13(1), 62 (2021).
   PubMed Web of Science ®Google Scholar